<DOC>
	<DOC>NCT00314288</DOC>
	<brief_summary>The primary purpose of the study is to investigate the anti-dyskinetic effect of several doses of sarizotan in Parkinson patients in order to generate information on the dose-response relationship (dose-finding).</brief_summary>
	<brief_title>Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Male or Female The subject is an outpatient Age 30 years or above Dyskinesias present during more than 25% of the waking day Dyskinesias at least moderately disabling Written informed consent Pregnancy and/or lactation Participation in another study within the last 30 days Dementia or other psychiatric illness that prevents provision of informed consent History of allergic disorders such as asthma Known hypersensitivity to the study treatment(s) Known hypersensitivity to ACTH</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Parkinson's Disease</keyword>
	<keyword>Dyskinesia</keyword>
	<keyword>L-dopa-induced dyskinesia</keyword>
</DOC>